Ortho-Cept: profile and news





[an error occurred while processing this directive]


Other information


Indication
For the prevention of pregnancy in women who elect to use this product as a method of contraception.

Pharmacology
Desogestrel is used as a female contraceptive. Desogestrel is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Desogestrel tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.

Mechanism Of Action
Binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like desogestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.

Drug Category
Contraceptives, Oral, Synthetic; ATC:G03AC09

Brand Names/Synonyms
Cerazette; Cyclessa; DESOGESTREL; Desogen; Desogestrel; Desogestrel [Usan:Ban:Inn]; Desogestrelum [Inn-Latin]; HSDB 3593; Kariva; Mircette; ORG 2969; Org-2969, Cerazette; Ortho-Cept

Dosage Forms
TABLET

Absorption
Following oral administration, the relative bioavailability of desogestrel compared to a solution, as measured by serum levels of etonogestrel, is approximately 100%.

Interactions
-->Interactions for Desogestrel:

Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72).

 
 


Chemical IUPAC Name
13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-ol

Chemical Formula
C22H30O

Half Life
27.8±7.2 hours

Drug Type
Approved Drug

# Accession No
APRD00762

CAS Registry Number
54024-22-5


Home | About | Cancers | Treatment | Medications
Copyright onconews.org 2005.
All Rights Reserved.
Google
 
Web onconews.org